We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of <sup>18</sup>F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging: <sup>18</sup>F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.
- Authors
De Man, Kathia; Piron, Sarah; Van Laeken, Nick; Delrue, Louke; Fonteyne, Valérie; Lumen, Nicolaas; Van den Broeck, Bliede; Kersemans, Ken; Ost, Piet; Schelfhout, Vanessa
- Abstract
Purpose: In this study, we evaluated the impact of 18F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed. Procedures: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the 18F-PSMA-11 findings. Results: The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on 18F-PSMA-11 PET/CT. Conclusion: 18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions.
- Subjects
POSITRON emission tomography computed tomography; MAGNETIC resonance imaging; SYSTEMIC family therapy; HISTOLOGY; QUESTIONNAIRES
- Publication
Molecular Imaging & Biology, 2022, Vol 24, Issue 5, p750
- ISSN
1536-1632
- Publication type
Article
- DOI
10.1007/s11307-022-01724-2